ACT1
ACT1 is a peptide that targets endogenous Cx43 by stabilizing its activity at gap junctions. ACT1 stabilizes gap junction intercellular communication in breast cancer cells. ACT1 enhances the activity of Tamoxifen and Lapatinib (HY-50898) in breast cancer. ACT1 can be used for breast cancer research[1].
Product Specifications
CAS Number
895547-36-1
UNSPSC
12352209
Target
Gap Junction Protein
Related Pathways
Cytoskeleton
Field of Research
Cancer
Smiles
O=C(N[C@@H](CCC(N)=O)C(N1[C@@H](CCC1)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CC4=CC=CC=C4)C(N5[C@@H](CCC5)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N6[C@@H](CCC6)C(N[C@@H](CC7=CNC8=CC=CC=C78)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N9[C@@H](CCC9)C(N[C@@H](CCCNC(N)=N)C(N%10[C@@H](CCC%10)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N
Molecular Formula
C150H238N48O34
Molecular Weight
3257.80
References & Citations
[1]Grek CL, et al. Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1. BMC Cancer. 2015 Apr 3;15:296.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
abx505360 96 Tests
Human Coiled-coil domain-containing protein 33 (CCDC33) ELISA Kit
Sign In for Pricing
View Details K1227902 1.0 µg DNA
LRCH1 sgRNA CRISPR Lentivector (Human) (Target 1)
Sign In for Pricing
View Details JOT-EKA0106Ra 96 wells
Rat very low density lipoprotein,VLDL ELISA KIT
Sign In for Pricing
View Details